Why Cg Oncology Stock Rocketed 7% Higher Today

Core Viewpoint - CG Oncology is a clinical-stage biotech company focused on developing treatments for non-muscle invasive bladder cancer (NMIBC), with a recent bullish research report boosting its share price significantly [1][2][3]. Company Overview - CG Oncology is currently concentrated on one type of cancer, NMIBC, and has a promising drug candidate, cretostimogene, which has shown efficacy and safety in clinical trials [3][4]. - The company has received a buy rating from Guggenheim with a price target of $90 per share, indicating a potential for more than double the current share price [2]. Market Potential - There is a large addressable market for NMIBC treatments, and a successful drug could provide significant pricing power for CG Oncology [4]. - The company is expected to seek FDA approval for its investigational drug next year, which adds to the optimism surrounding its prospects [5].